Drug reference
ocrelizumab
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Drug class
Central Nervous System (MS Drugs)
Mechanism of action
Humanized monoclonal antibody designed to selectively target CD20, a cell surface antigen present on pre-B and mature B lymphocytes, Following cell surface binding to B lymphocytes, ocrelizumab results in antibody-dependent cellular cytolysis and complement-mediated lysis
Common side effects
- Infusion-related reactions
- Skin infections
- Decreased neutrophil counts
- Lower respiratory tract infections
- Upper respiratory tract infections
Related conditions
Frequently asked questions
What drug class is ocrelizumab?
ocrelizumab belongs to: Central Nervous System.
How does ocrelizumab work?
Humanized monoclonal antibody designed to selectively target CD20, a cell surface antigen present on pre-B and mature B lymphocytes, Following cell surface binding to B lymphocytes, ocrelizumab results in antibody-dependent cellular cytolysis and complement-mediated lysis
What are the common side effects of ocrelizumab?
Infusion-related reactions, Skin infections, Decreased neutrophil counts, Lower respiratory tract infections, Upper respiratory tract infections
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.